Investor Service Announcement no. 8/2007
To: OMX Nordic Exchange Hørsholm, Denmark, November 20, 2007
LifeCycle Pharma to Host Third Quarter 2007 Financial Results Conference Call
and Webcast
Hørsholm, Denmark, November 20, 2007; LifeCycle Pharma A/S (OMX: LCP) (the
“Company” or “LCP”), an emerging specialty pharmaceutical company, will announce
financial results for the third quarter ended September 30, 2007 after the close
of the Danish financial market on Tuesday, November 27, 2007. LCP's Management
Team will host an accompanying conference call to discuss the financial results
the following day, Wednesday, November 28, 2007 at 15:00 CET (Copenhagen); 14:00
GMT (London); 9:00 a.m. ET (New York); 6:00 a.m. PT (San Francisco).
To access the live telephonic broadcast, callers may dial the following numbers:
Denmark: +45 80 88 49 65 (toll-free)
U.S.: (800) 299-7635 (toll-free)
Others: +1 617 786 2901
Confirmation code for all participants: 69939060
A live audio webcast of the call will be available via the “Investors” section
of the Company's website at www.lcpharma.com. Participants are urged to log on
to the website 15 minutes prior to the scheduled start time to download and
install any necessary software.
An audio replay of the conference call will be available from 17:00 CET
(Copenhagen); 16:00 GMT (London); 11:00 a.m. ET (New York); 8:00 a.m. PT (San
Francisco) on Wednesday, November 28, 2007 through Wednesday, December 5, 2007
by dialling the following numbers:
U.S.: (888) 286-8010
Others: +1 617 801 6888
Confirmation code for all callers: 50677341
Additionally, the audio webcast will be available on the Company's website,
www.lcpharma.com, for 30 days. The financial results press release and interim
report will also be accessible on the Company's website.
About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceuticals company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop drugs
with enhanced absorption and thereby increased bioavailability. Currently, the
Company has a diversified near- and medium-term pipeline, including a product
ready for US commercialization, four product candidates in clinical trials and
four in preclinical stages of development. LCP is listed on the OMX Nordic
Exchange under the trading symbol (OMX: LCP). For further information, please
visit www.lcpharma.com.
Contact:
Michael Wolff Jensen
EVP and CFO
+45 4074-6244; MWJ@lcpharma.com
Francesca M. DeMartino
Director, Investor Relations
(646) 200-8504; FDM@lcpharma.com
---oo0oo---
LifeCycle Pharma to Host Third Quarter 2007 Financial Results Conference Call and Webcast
| Source: Veloxis Pharmaceuticals A/S
Attachments
